Navigation Links
Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations

SAN DIEGO, Nov. 19 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that Jorgine Ellerbrock has joined the Company as senior vice president, operations.

"We are pleased to add Jorgine's extensive experience in operations and supply chain management to our already strong senior management team," said Carl Hull, Gen-Probe's executive vice president and chief operating officer.

Ms. Ellerbrock, 46, joins the Company from Invitrogen Corporation, where she had been vice president, operations, since 2004, most recently for the Molecular Biology Business. Prior to joining Invitrogen, she held positions of increasing responsibility with GE Healthcare Bio-Sciences (formerly Amersham Biosciences). She served as vice president, operations from 2002 to 2004, and vice president, genomics product management, in 2002. Before joining Amersham in 1998, Ms. Ellerbrock was employed by Roche Molecular Systems and Gen-Probe. She earned a BS in microbiology and an MBA from San Diego State University.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 24 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning plans and objectives of management are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include, but are not limited to, the risk that we cannot retain key executives. The foregoing sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


Michael Watts

Senior director, investor relations and corporate communications


SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Richard Greco Joins Mediware Board
2. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
3. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
4. Dr. Mahesh Ramachandran Joins Marianjoy Medical Group
5. Nick Childs Joins Grey New York as Director of Content Development
6. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
7. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
8. NASN Joins Partnership to Fight Chronic Disease
9. AstraZeneca Joins Local Walking Movement
10. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
11. Fund Manager Joins Board of GSI Securitization Inc.
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... GKhair & Tibolli ... the San Juan Beauty Show held on November 8th and 9th at the Puerto ... media personalities, hair artists, renowned beauticians and top of the line fashion journalists. The ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that ... Program with competencies in the Application Development, demonstrating a “best-in-class” ability and ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... product dealer. Joining more than 30 HealthPostures’ dealers located throughout the United States, ... increase the number of corporate, industrial, manufacturing and government workers and organizational leaders ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... patented products, announces the Unstoppable Swappables, a household invention that provides an economical ... $2 billion a year and is growing at 2.6%," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology: